{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-251917","form_type":"8-K","ticker":"ALXO","cik":"0001810182","company_name":"ALX ONCOLOGY HOLDINGS INC","filed_at":"2023-10-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.580356+00:00","generated_at":"2026-06-10T03:34:28.817763+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ALX Oncology prices $55M public offering of common stock and pre-funded warrants","bullets":["Priced public offering of 7,370,690 shares at $6.38/share and pre-funded warrants for 1,250,000 shares at $6.379/warrant.","Gross proceeds expected ~$55M before underwriting discounts; offering to close Oct 10, 2023.","Net proceeds to fund evorpacept clinical development including ASPEN-06 trial, working capital.","Underwriters granted 30-day option to purchase up to 1,293,103 additional shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-251917","json":"https://secwatch.observer/filing/0001193125-23-251917.json","markdown":"https://secwatch.observer/filing/0001193125-23-251917.md","text":"https://secwatch.observer/filing/0001193125-23-251917.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810182/000119312523251917/0001193125-23-251917-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810182/000119312523251917/d534693d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T03:34:28.817763+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"10efcdc0ca8acc43a2b30ac8f6e5e99b218aa8cf","claim":"ALX ONCOLOGY HOLDINGS INC entered into Underwriting Agreement with Piper Sandler & Co. and Cantor Fitzgerald & Co. valued at approximately $55.0 million (effective 2023-10-04).","evidence_excerpt":"On October 4, 2023, ALX Oncology Holdings Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Piper Sandler & Co. and Cantor Fitzgerald & Co., as representatives (the “Representatives”) of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale (the “Offering”) of 7,370,690 shares of the Company’s common stock, par value $0.001 per share, at a price to the public of $6.38 per share (the “Underwritten Shares”) and pre-funded warrants (the “Pre-Funded Warrants”) to purchase 1,250,000 shares of the Company’s common stock at a price to the public of $6.379 per Pre-Funded Warrant.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810182/000119312523251917/0001193125-23-251917-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Piper Sandler & Co. and Cantor Fitzgerald & Co."},{"label":"Value","value":"approximately $55.0 million"},{"label":"Effective","value":"2023-10-04"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}